Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma

Cancer and Metastasis Reviews

Volumn 29, Issue SUPPL. 1, 2010, Pages

  Calvo, Emiliano ^a   Maroto, Pablo ^b   Del Muro, Xavier García ^c   Climent, Miguel Ángel ^d   González Larriba, José Luis ^e   Esteban, Emilio ^f   López, Rafael ^g   Paz Ares, Luis ^h   Bellmunt, Joaquim ⁱ   Castellano, Daniel ^j  

^a Hospital de Madrid CIOCC   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

ⁱ HOSPITAL DEL MAR   (Spain)

^j HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

more..

Author keywords

Cancer treatment; Renal cell carcinoma; Spanish Oncology Genitourinary Group

Indexed keywords

AFINITOR; ALPHA INTERFERON; BEVACIZUMAB; EVEROLIMUS; INTERLEUKIN 2; PAZOPANIB; PHOSPHOTRANSFERASE INHIBITOR; PLACEBO; RECOMBINANT ALPHA INTERFERON; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TUMOR MARKER; UNCLASSIFIED DRUG; VOTRIENT;

ADVANCED CANCER; CANCER DIAGNOSIS; CANCER THERAPY; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TARGETING; HUMAN; KIDNEY CARCINOMA; MEDICAL SOCIETY; METASTASIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SPAIN; CARCINOMA, RENAL CELL; ETHNOLOGY; KIDNEY NEOPLASMS; ONCOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC);

CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; KIDNEY NEOPLASMS; MEDICAL ONCOLOGY; SPAIN;

EID: 77954548932     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-010-9231-6     Document Type: Review

References (62)

1. A Jemal R Siegel E Ward, et al. 2009 Cancer statistics, 2009 CA: A Cancer Journal for Clinicians 59 225 249 10.3322/caac.20006
2. J Bellmunt E Calvo D Castellano, et al. 2009 Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer Cancer Chemotherapy and Pharmacology 63 Suppl 1 S1 S13 10.1007/s00280-009-0955-3 19259675
3. RJ Amato 2000 Chemotherapy for renal cell carcinoma Seminars in Oncology 27 177 186 1:CAS:528:DC%2BD3cXivFOgtbY%3D 10768596
4. JS Lam JT Leppert RA Figlin, et al. 2005 Surveillance following radical or partial nephrectomy for renal cell carcinoma Current Urology Reports 6 7 18 10.1007/s11934-005-0062-x 15610692
5. RM Bukowski 2009 Prognostic factors for survival in metastatic renal cell carcinoma: update 2008 Cancer 115 2273 2281 10.1002/cncr.24226 1:CAS:528:DC%2BD1MXmtVOksbg%3D 19402065
6. G Lughezzani U Capitanio C Jeldres, et al. 2009 Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma: a population-based perspective Cancer 115 5680 5687 10.1002/cncr.24682 19824083
7. B Ljungberg G Landberg FI Alamdari 2000 Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy Scandinavian Journal of Urology and Nephrology 34 246 251 10.1080/003655900750041979 1:STN:280:DC%2BD3Mzgs12ntw%3D%3D 11095082 (Pubitemid 32061331)
8. MB Atkins MS Ernstoff RA Figlin, et al. 2007 Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference Clinical Cancer Research 13 667s 670s 10.1158/1078-0432.CCR-06-2231 17255291 (Pubitemid 46220081)
9. HS Tunuguntla M Jorda 2008 Diagnostic and prognostic molecular markers in renal cell carcinoma Journal d'Urologie 179 2096 2102 10.1016/j.juro.2008.01. 083 1:CAS:528:DC%2BD1cXntlSmtr0%3D
10. B Escudier T Eisen WM Stadler, et al. 2009 Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial Journal of Clinical Oncology 27 3312 3318 10.1200/JCO.2008.19.5511 1:CAS:528:DC%2BD1MXpvFejt7w%3D 19451442
11. DY Heng W Xie MM Regan, et al. 2009 Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study Journal of Clinical Oncology 27 5794 5799 10.1200/JCO.2008.21.4809 1:CAS:528:DC%2BC3cXhtVWitr4%3D 19826129
12. T Klatte PN Rao M de Martino, et al. 2009 Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma Journal of Clinical Oncology 27 746 753 10.1200/JCO.2007.15.8345 19124809
13. RJ Motzer MD Michaelson BG Redman, et al. 2006 Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma Journal of Clinical Oncology 24 16 24 10.1200/JCO.2005.02.2574 1:CAS:528:DC%2BD28Xot1ChtA%3D%3D 16330672 (Pubitemid 46630489)
14. RJ Motzer BI Rini RM Bukowski, et al. 2006 Sunitinib in patients with metastatic renal cell carcinoma Jama 295 2516 2524 10.1001/jama.295.21.2516 1:CAS:528:DC%2BD28XlsV2rtLk%3D 16757724 (Pubitemid 43854967)
15. Figlin, R. A., Hutson, T. E., Tomczak, P., et al (2008). Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). Chicago: ASCO Annual Meeting
16. RJ Motzer TE Hutson P Tomczak, et al. 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma The New England Journal of Medicine 356 115 124 10.1056/NEJMoa065044 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D 17215529 (Pubitemid 46089672)
17. RJ Motzer TE Hutson P Tomczak, et al. 2009 Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma Journal of Clinical Oncology 27 3584 3590 10.1200/JCO.2008.20.1293 1:CAS:528:DC%2BD1MXhtVOnu7nI 19487381
18. D Cella JZ Li JC Cappelleri, et al. 2008 Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial Journal of Clinical Oncology 26 3763 3769 10.1200/JCO.2007.13.5145 1:CAS:528:DC%2BD1cXhtVGjs7rJ 18669464
19. TK Choueiri J Bellmunt 2009 Sunitinib in renal-cell carcinoma: expanded indications The Lancet Oncology 10 740 10.1016/S1470-2045(09)70185-8 19615941
20. ME Gore C Szczylik C Porta, et al. 2009 Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial The Lancet Oncology 10 757 763 10.1016/S1470-2045(09)70162-7 1:CAS:528:DC%2BD1MXptlalsrc%3D 19615940
21. EMEA. (2009). Sunitinib (Sutent®)-summary of product characteristics. http://www.ema.europa.eu/humandocs/PDFs/EPAR/sutent/emea-combined-h687en.pdf.
22. FDA. (2007). Sunitinib (Sutent®)-full prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2007/ 021968s002s003s004s005s006lbl.pdf.
23. H Akaza T Tsukamoto M Murai, et al. 2007 Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma Japanese Journal of Clinical Oncology 37 755 762 10.1093/jjco/hym095 17951335 (Pubitemid 350120299)
24. B Escudier T Eisen WM Stadler, et al. 2007 Sorafenib in advanced clear-cell renal-cell carcinoma The New England Journal of Medicine 356 125 134 10.1056/NEJMoa060655 1:CAS:528:DC%2BD2sXksVKitg%3D%3D 17215530 (Pubitemid 46089673)
25. B Escudier C Szczylik TE Hutson, et al. 2009 Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma Journal of Clinical Oncology 27 1280 1289 10.1200/JCO.2008.19.3342 1:CAS:528:DC%2BD1MXktFKhsb8%3D 19171708
26. EMEA. (2009). Sorafenib (Nexavar®)-summary of product characteristics. http://www.ema.europa.eu/humandocs/PDFs/EPAR/nexavar/emea- combined-h690en.pdf.
27. FDA. (2007). Sorafenib (Nexavar®)-full prescribing information: http://www.accessdata.fda.gov/drugsatfda-docs/label/2007/ 021923s004s005s006s007lbl.pdf.
28. RM Bukowski U Yasothan P Kirkpatrick 2010 Pazopanib Nature Reviews Drug Discovery 9 17 18 10.1038/nrd3073 1:CAS:528:DC%2BD1MXhs1aqtbfE 20043026
29. CN Sternberg ID Davis J Mardiak, et al. 2010 Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial Journal of Clinical Oncology 28 1061 1068 10.1200/JCO.2009.23.9764 1:CAS:528:DC%2BC3cXktF2lt78%3D 20100962
30. RE Hawkins SJ Hong A Ulys, et al. 2009 An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma (RCC) Journal of clinical oncology (Meeting Abstracts) 27 5110
31. FDA. (2009). Pazopanib (Votrient®)-full prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/022465lbl.pdf.
32. HF Dvorak 2002 Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy Journal of Clinical Oncology 20 4368 4380 10.1200/JCO.2002.10.088 1:CAS:528:DC%2BD38Xpt1CjtL0%3D 12409337 (Pubitemid 35266299)
33. B Escudier A Pluzanska P Koralewski, et al. 2007 Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2103 2111 10.1016/S0140-6736(07)61904-7 18156031 (Pubitemid 350296300)
34. Rini, B. I., Halabi, S., Rosenberg, J. E., et al. (2008). CALGB 90206: a phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. San Francisco: Genitourinary Cancers Symposium
35. BJ Escudier J Bellmunt S Negrier, et al. 2009 Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV)∈+∈interferon-{alpha}2a (IFN) in metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology (Meeting Abstracts) 27 5020
36. BI Rini S Halabi J Rosenberg, et al. 2009 Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206 Journal of Clinical Oncology (Meeting Abstracts) 27 LBA5019
37. EMEA. (2009). Bevacizumab (Avastin®)-summary of product characteristics. http://www.ema.europa.eu/humandocs/PDFs/EPAR/avastin/emea- combined-h582en.pdf.
38. FDA. (2009). Bevacizumab (Avastin®)-full prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/125085s0168lbl.pdf.
39. G Hudes M Carducci P Tomczak, et al. 2007 Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma The New England Journal of Medicine 356 2271 2281 10.1056/NEJMoa066838 1:CAS:528:DC%2BD2sXmtVKkurs%3D 17538086 (Pubitemid 46849157)
40. S Parasuraman G Hudes D Levy, et al. 2007 Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-{alpha} (IFN) or the combination of IFN∈+∈TEMSR Journal of Clinical Oncology (Meeting Abstracts) 25 5049
41. EMEA. (2009). Temsirolimus (Torisel®)-summary of product characteristics. http://www.ema.europa.eu/humandocs/PDFs/EPAR/torisel/emea- combined-h799en.pdf.
42. FDA. (2007). Temsirolimus (Torisel®)-full prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2007/022088lbl.pdf.
43. RJ Motzer B Escudier S Oudard, et al. 2008 Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 449 456 10.1016/S0140-6736(08)61039-9 1:CAS:528:DC%2BD1cXps1GmsLY%3D 18653228
44. D Wiederkehr CJ Howe R Casciano, et al. 2009 Overall survival among metastatic renal cell carcinoma patients corrected for crossover using inverse probability of censoring weights: analyses from the everolimus phase III trial European Journal of Cancer Supplements 7 432 10.1016/S1359-6349(09)71464-8
45. EMEA. (2009). Everolimus (Afinitor®)-summary of product characteristics. http://www.ema.europa.eu/humandocs/PDFs/EPAR/afinitor/emea- combined-h1038en.pdf.
46. FDA. (2009). Everolimus (Afinitor®)-full prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/022334lbl.pdf.
47. AJ Pantuck DB Seligson T Klatte, et al. 2007 Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy Cancer 109 2257 2267 10.1002/cncr.22677 1:CAS:528:DC%2BD2sXmvVKjsLk%3D 17440983 (Pubitemid 46801555)
48. RH Thompson X Zang CM Lohse, et al. 2008 Evaluation of soluble B7x as a serum marker in patients with clear cell renal cell carcinoma Journal of Clinical Oncology (Meeting Abstracts) 26 5052
49. MH Bui D Seligson KR Han, et al. 2003 Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy Clinical Cancer Research 9 802 811 1:CAS:528:DC%2BD3sXhtVKksbg%3D 12576453
50. JJ Patard P Fergelot PI Karakiewicz, et al. 2008 Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma International Journal of Cancer 123 395 400 10.1002/ijc.23496 1:CAS:528:DC%2BD1cXnsF2jtrs%3D (Pubitemid 351842025)
51. H Kim S Yi H Jun, et al. 2008 Use of biomakers to predict outcomes of immunotherapy for metastatic renal cell carcinoma Journal of Clinical Oncolog (Meeting Abstracts) 26 16015
52. S Tanimoto T Fukumori G El-Moula, et al. 2008 Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor The Journal of Medical Investigation 55 106 111 10.2152/jmi.55.106 18319552 (Pubitemid 351643600)
53. T Klatte DB Seligson SB Riggs, et al. 2007 Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma Clinical Cancer Research 13 7388 7393 10.1158/1078-0432.CCR-07-0411 1:CAS:528:DC%2BD2sXhsVCktr3N 18094421
54. MH Bui H Visapaa D Seligson, et al. 2004 Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma Journal d'Urologie 171 2461 2466 10.1097/01.ju.0000116444.08690.e2 (Pubitemid 38625515)
55. RH Weiss AD Borowsky D Seligson, et al. 2007 p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches Journal d'Urologie 177 63 68 10.1016/j.juro.2006.08.073 1:CAS:528:DC%2BD2sXmslKlug%3D%3D discussion 68-9 (Pubitemid 44879463)
56. HL Kim D Seligson X Liu, et al. 2005 Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma Journal d'Urologie 173 1496 1501 10.1097/01.ju.0000154351.37249.f0 1:CAS:528:DC%2BD2MXjtFalsrk%3D (Pubitemid 40524757)
57. O Shvarts D Seligson J Lam, et al. 2005 p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma Journal d'Urologie 173 725 728 10.1097/01.ju.0000152354. 08057.2a 1:CAS:528:DC%2BD2MXhtl2msLg%3D (Pubitemid 40239328)
58. RM Bukowski T Eisen C Szczylik, et al. 2007 Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis Journal of Clinical Oncology (Meeting Abstracts) 25 5023
59. PH Patel RS Chadalavada NM Ishill, et al. 2008 Hypoxia-inducible factor (HIF) 1{alpha} and 2{alpha} levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC) Journal of Clinical Oncology (Meeting Abstracts) 26 5008
60. E Jaeger F Waldman R Roydasgupta, et al. 2008 Array-based comparative genomic hybridization (CGH) identifies chromosomal imbalances between Interleukin-2 complete and non-responders Journal of Clinical Oncology (Meeting Abstracts) 26 5043
61. PW Faber SA Vaziri L Wood, et al. 2008 Potential non-synonymous single nucleotide polymorphisms (nsSNPs) associated with toxicity in metastatic clear cell renal cell carcinoma (MCCRCC) patients (pts) treated with sunitinib Journal of Clinical Oncology (Meeting Abstracts) 26 5009
62. TK Choueiri SA Vaziri E Jaeger, et al. 2008 von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma Journal d'Urologie 180 860 865 10.1016/j.juro.2008.05.015 1:CAS:528:DC%2BD1cXhtVKmsbvE discussion 865-6